Retrieved records
Source fields and source URLs are retained in the generated datasets. Counts are scoped to the queries and filters documented on this page.
Sources, definitions and limitations
What the site includes, how records are grouped, and where coverage is limited.
Reviewed classification
A version-controlled ontology connects known intervention aliases to canonical assets, target families, and modalities. Unmatched terms remain unclassified.
Derived measures
Study counts use distinct registry IDs. Target groups can overlap when a study includes several therapies, including background treatments and comparators.
Refresh checks
Each weekly run retrieves every source and checks identifiers, references and key calculations. Publication requires a complete successful refresh. If retrieval or validation fails, the live snapshot is kept and the workflow reports the failure.
Public systems and retrieval scope
Studies, sponsors, interventions, phases, statuses, dates, results flags, and registered locations
API v2 condition query for “Multiple Myeloma”; headline active counts are limited to interventional studies in four documented active statuses.
Annual literature counts, target-linked query counts, and a browsable recent citation sample
Annual and recent-stream queries require the disease phrase in the citation title. Target counts use reviewed target and therapy terms in titles or abstracts over a three-year window.
Project records, organizations, investigators, fiscal years, and award amounts
Projects require multiple myeloma in the project title and cover the current and two prior fiscal years.
Oncology approval notifications and current oncology shortage records
Approval rows require a multiple-myeloma phrase. Shortages are current oncology records matched to reviewed therapy aliases and remain presentation-specific.
Structured Product Label versions for a reviewed therapy list
Records are retrieved by reviewed drug name and deduplicated by DailyMed set ID. The current label at DailyMed remains authoritative.
Centrally managed medicine status, indication text, and record updates
Records require multiple myeloma in the therapeutic indication or plasma cell myeloma in the therapeutic-area field.
Snapshot details
- Disease query
- "Multiple Myeloma"
- Trial scope
- All returned registry records; headline metrics use interventional studies with recruiting, active-not-recruiting, not-yet-recruiting or enrolling-by-invitation status.
- PubMed target window
- 2024–2026
- Dataset version
- f2a668ff158f
- Source retrieval
- 11/4/2026, 11:00:24 PM EST
- Refresh schedule
- Weekly on Monday at 07:17 US Eastern time
Important interpretation limits
- Registry dates, statuses, enrollment, sponsor, and location fields are submitted and revised by study record owners.
- PubMed target counts can overlap because one record may match more than one reviewed target or therapy query.
- Each intervention currently has one target label. Multi-target agents, unresolved names and dose variants may be incompletely represented. Unqueried literature targets are marked separately from zero matches.
- NIH amounts reflect application records returned by RePORTER and can change during the current fiscal year.
- DailyMed, EMA, and FDA shortage matches are constrained by reviewed therapy terms and should not be generalized beyond the linked source record.
Appropriate use
This application is a public-data landscape reference. It is not medical advice, clinical decision support, regulatory advice, market-share reporting, investment advice, or a validated commercial intelligence product. Source records may be incomplete, delayed, or revised by their publishers. The header date is the oldest successful source retrieval in the published snapshot. New snapshots are published only after all sources refresh. Therapy entities may include unresolved registry names and regimen strings; they are not a count of distinct development programs. A highest study phase does not establish a medicine's approval status.